Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYXATA vs COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise capacity and delay clinical worsening,Treatment of PAH in combination with other PAH therapies
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.
5-10 g orally once or twice daily, maximum 30 g/day.
Terminal elimination half-life is 12–15 hours in adults with normal renal function; extends to 22–30 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and up to 48 hours in severe impairment (Cr Cl <30 m L/min).
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Primarily hepatic via CYP3A4 and CYP2C19; minor contribution from UGT1A1, UGT1A3, UGT1A9. Active metabolite (M14) via dealkylation.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Renal excretion accounts for approximately 70% of elimination (60% unchanged, 10% as metabolites); biliary/fecal excretion accounts for 25% (primarily as metabolites); minor metabolic clearance (5%) via CYP3A4.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
88–92% bound to albumin and alpha-1-acid glycoprotein.
Not significantly absorbed; binding not applicable
0.8–1.2 L/kg, indicating extensive extravascular distribution into tissues including brain and myocardium.
Not applicable (non-absorbed; confined to gastrointestinal lumen)
Oral: 35–45% (due to first-pass metabolism); IM: 80–90%; IV: 100%.
Oral: <0.05% (negligible systemic absorption)
No dosage adjustment is required for renal impairment. Landiolol is minimally renally excreted (approximately 1% unchanged). However, use caution in patients with severe renal impairment (Cr Cl < 30 m L/min) due to limited data.
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
For mild hepatic impairment (Child-Pugh Class A): No dosage adjustment needed. For moderate to severe hepatic impairment (Child-Pugh Class B or C): Reduce initial infusion rate to 0.05 mg/kg/min and titrate cautiously; maximum infusion rate of 0.2 mg/kg/min is recommended due to reduced clearance.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
Weight-based dosing: Loading dose of 0.125 mg/kg intravenously over 1 minute, followed by continuous infusion starting at 0.05 mg/kg/min, titrated to effect. Maximum infusion rate is 0.3 mg/kg/min. Safety and efficacy established in pediatric patients aged 1 to <18 years.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
Elderly patients (≥65 years): Start at the lower end of the dosing range (initial infusion rate of 0.05 mg/kg/min) and titrate slowly due to potential decreased hepatic function and increased sensitivity. No specific dose adjustment mandated, but monitor heart rate and blood pressure closely.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
Embryofetal toxicity: Must be avoided in pregnancy; females of reproductive potential must use reliable contraception and have monthly pregnancy tests.
No FDA black box warning.
Hepatotoxicity (requires monthly liver function monitoring); fluid retention (peripheral edema, may require diuretics); hematologic changes (hemoglobin decrease, requires periodic monitoring); pulmonary veno-occlusive disease (PVOD) should be excluded.
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
Pregnancy (absolute); hypersensitivity to macitentan or any component; concomitant use with strong CYP3A4 inducers (e.g., rifampin) (relative); severe hepatic impairment (Child-Pugh C) (relative).
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
Avoid alcohol and grapefruit juice. High-fat meals may delay absorption; take on empty stomach for consistent effect.
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
No human data; M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise against breastfeeding during therapy.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
No pharmacokinetic data in pregnancy; no dose adjustment guidelines available. Use with caution and therapeutic drug monitoring if applicable.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
KYXATA (potassium oxyrate) is a CNS depressant; avoid concurrent use with alcohol or other sedatives. Monitor for respiratory depression, especially in elderly or COPD patients. Taper dose to prevent withdrawal seizures. Not a controlled substance but carries abuse potential.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating machinery until you know how KYXATA affects you.,Do not drink alcohol while taking this medication.,Do not stop suddenly; abrupt discontinuation may cause seizures.,Report any unusual changes in mood, thoughts, or behavior.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYXATA vs COLESTID, answered by our medical review team.
KYXATA is a Unknown that works by Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).. COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYXATA and COLESTID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYXATA is: KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.. The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYXATA and COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYXATA is classified as Category C. No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.. COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.